Logo image of CVKD

CADRENAL THERAPEUTICS INC (CVKD) Stock Fundamental Analysis

NASDAQ:CVKD - Nasdaq - US1276362076 - Common Stock - Currency: USD

14.61  -0.88 (-5.68%)

Fundamental Rating

2

Overall CVKD gets a fundamental rating of 2 out of 10. We evaluated CVKD against 195 industry peers in the Pharmaceuticals industry. While CVKD has a great health rating, there are worries on its profitability. CVKD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CVKD had negative earnings in the past year.
CVKD had a negative operating cash flow in the past year.
CVKD Yearly Net Income VS EBIT VS OCF VS FCFCVKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

CVKD has a Return On Assets of -161.36%. This is amonst the worse of the industry: CVKD underperforms 86.67% of its industry peers.
CVKD's Return On Equity of -209.93% is on the low side compared to the rest of the industry. CVKD is outperformed by 69.74% of its industry peers.
Industry RankSector Rank
ROA -161.36%
ROE -209.93%
ROIC N/A
ROA(3y)-354.52%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CVKD Yearly ROA, ROE, ROICCVKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVKD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVKD Yearly Profit, Operating, Gross MarginsCVKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

CVKD has more shares outstanding than it did 1 year ago.
CVKD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CVKD Yearly Shares OutstandingCVKD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M
CVKD Yearly Total Debt VS Total AssetsCVKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

CVKD has an Altman-Z score of 0.22. This is a bad value and indicates that CVKD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.22, CVKD is in line with its industry, outperforming 54.36% of the companies in the same industry.
CVKD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.22
ROIC/WACCN/A
WACCN/A
CVKD Yearly LT Debt VS Equity VS FCFCVKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 4.32 indicates that CVKD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.32, CVKD is in the better half of the industry, outperforming 64.62% of the companies in the same industry.
A Quick Ratio of 4.32 indicates that CVKD has no problem at all paying its short term obligations.
The Quick ratio of CVKD (4.32) is better than 65.13% of its industry peers.
Industry RankSector Rank
Current Ratio 4.32
Quick Ratio 4.32
CVKD Yearly Current Assets VS Current LiabilitesCVKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

CVKD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.99%.
EPS 1Y (TTM)5.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.05% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.65%
EPS Next 2Y31.95%
EPS Next 3Y21.99%
EPS Next 5Y15.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVKD Yearly Revenue VS EstimatesCVKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 20M 40M 60M 80M 100M
CVKD Yearly EPS VS EstimatesCVKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CVKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CVKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVKD Price Earnings VS Forward Price EarningsCVKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVKD Per share dataCVKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

CVKD's earnings are expected to grow with 21.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.95%
EPS Next 3Y21.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CVKD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (6/5/2025, 8:00:01 PM)

14.61

-0.88 (-5.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners5.53%
Inst Owner Change382.41%
Ins Owners4.51%
Ins Owner Change0%
Market Cap28.78M
Analysts82.5
Price Target36.38 (149.01%)
Short Float %3.7%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.86%
Min EPS beat(2)-56.79%
Max EPS beat(2)-24.94%
EPS beat(4)0
Avg EPS beat(4)-41.42%
Min EPS beat(4)-73.01%
Max EPS beat(4)-10.93%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)-14.88%
EPS NY rev (3m)-38.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.71
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-9.26
EYN/A
EPS(NY)-2.24
Fwd EYN/A
FCF(TTM)-5.16
FCFYN/A
OCF(TTM)-5.16
OCFYN/A
SpS0
BVpS3.1
TBVpS3.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.36%
ROE -209.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-354.52%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.32
Quick Ratio 4.32
Altman-Z 0.22
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.33%
EPS Next Y37.65%
EPS Next 2Y31.95%
EPS Next 3Y21.99%
EPS Next 5Y15.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.34%
EBIT Next 3Y-47.56%
EBIT Next 5Y-27.83%
FCF growth 1Y-108.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.41%
OCF growth 3YN/A
OCF growth 5YN/A